Revelation Biosciences granted restricted stock awards to CEO James Rolke (208,076 shares) and CFO Chester S. Zygmont, III (208,073 shares), effective August 17, 2026. Vesting is contingent on service or achieving specific market capitalization milestones ($30M, $60M, $90M, $120M) over two to four years, with full acceleration upon a Change in Control or qualifying termination events. Revelation Biosciences operates in the biotechnology industry, focusing on developing diagnostic and therapeutic technologies.